Sneaky side effects and ineffectiveness of an immunotherapy with ipilimumab in a case of metastatic melanoma

Ipilimumab is an anti-CTLA-4 antibody that is approved for the treatment of metastatic malignant melanoma. Side-effects are mostly immune-mediated and in many cases the lack of specific symptoms leads to delayed diagnosis and treatment of adverse events. We present the case of a female patient who e...

Descripción completa

Detalles Bibliográficos
Autores principales: Krecké, Nathalie, Zimmer, Anna, Friesenhahn-Ochs, Bettina, Müller, Cornelia S. L., Vogt, Thomas, Pföhler, Claudia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4977105/
https://www.ncbi.nlm.nih.gov/pubmed/27574531
http://dx.doi.org/10.1080/19381980.2016.1199307

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4977105/
https://www.ncbi.nlm.nih.gov/pubmed/27574531
http://dx.doi.org/10.1080/19381980.2016.1199307

Ejemplares similares